Antibodies for Treatment of Clostridium difficile Infection | Zendy

David P. Humphreys | Zendy; Mark H. Wilcox | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibodies for Treatment of Clostridium difficile Infection

Author(s) -

David P. Humphreys,

Mark H. Wilcox

Publication year - 2014

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00116-14

Subject(s) - clostridium difficile , antibody , microbiology and biotechnology , clostridium infections , virology , medicine , immunology , antibiotics , biology

Antibodies for the treatment of Clostridium difficile infection (CDI) have been demonstrated to be effective in the research and clinical environments. Early uncertainties about molecular and treatment modalities now appear to have converged upon the systemic dosing of mixtures of human IgG1. Although multiple examples of high-potency monoclonal antibodies (MAbs) exist, significant difficulties were initially encountered in their discovery. This minireview describes historical and contemporary MAbs and highlights differences between the most potent MAbs, which may offer insight into the pathogenesis and treatment of CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research